Activation of meningeal 5-HT(2B) receptors: An early step in the generation of migraine headache?

European Journal of Neuroscience

Volumn 8, Issue 5, 1996, Pages 959-967

  Schmuck, K ^a   Ullmer, C ^a   Kalkman, H O ^a   Probst, A ^a   Lubbert, H ^a  

^a Preclinical Research   (Switzerland)

Author keywords

Human meningeal tissue; Nitric oxide; RT PCR; Serotonin receptor

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; NITRIC OXIDE; PHOSPHATIDYLINOSITOL; RADIOLIGAND; SEROTONIN 1C RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 4 RECEPTOR;

ANIMAL TISSUE; ARTERY MUSCLE; ARTICLE; BLOOD VESSEL; BRAIN ARTERY; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; HYDROLYSIS; LIGAND BINDING; MENINX; MESSENGER RNA SYNTHESIS; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT; RECEPTOR AFFINITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE RELAXATION; SWINE; TRIGEMINAL NERVE;

EID: 0029967853     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1460-9568.1996.tb01583.x     Document Type: Article

References (50)

1. Aguzzi, A. (1990) Rapid RNA extraction from tissue and cultured cells. In Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. and Struhl, K. (eds), Current Protocols in Molecular Biology, Supplement 9. Wiley Interscience, New York, p. 1.
2. Anthony, M., Lord, G. D. A. and Lance, J. W. (1978) Controlled trials of cimetidine in migraine and cluster headache. Headache, 18, 261–264.
3. Aulakh, C. S., Hill, J. L. and Murphy, D. L. (1992) Effects of various serotonin receptor subtype‐selective antagonists alone and on m ‐chlorophenyl‐piperazine‐induced neuroendocrine changes in rats. J. Pharmacol. Exp. Ther., 263, 588–595.
4. Brewerton, T. D., Murphy, D. L., Mueller, E. A. and Jimerson, D. C. (1988) Induction of migrainelike headaches by serotonin agonist m ‐chlorophenylpiperazine. Clin. Pharmacol. Ther., 43, 605–609.
5. Buzzi, M. G., Carter, W. B., Shimizu, T., Heath, H. and Moskowitz, M. A. (1991) Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology, 30, 1193–1200.
6. Chan‐Palay, V. (1976) Serotonin axons in the supra‐ and subependymal plexuses and in the leptomeninges; their roles in local alterations of cerebrospinal fluid and vasomotor activity. Brain Res., 102, 103–130.
7. Curzon, G., Barrie, M. and Wilkinson, M. I. P. (1969) Relationships between headache and amine changes after administration of reserpine to migrainous patients. J. Neurol. Neurosurg. Psychiatry, 32, 555–561.
8. Del Bene, E., Anselmi, B. and Del Bianco, P. L. (1977) Fenfluramine headache: a biochemical and monoamine receptorial human study. In Sicuteri, F. (ed.), Headache: New Vistas, Biomedical Press, Florence, pp. 101–109.
9. Doenicke, A., Brand, J. and Perrin, V. L. (1988) Possible benefit of GR43175, a novel 5‐HT 1 ‐like receptor agonist, for the acute treatment of severe migraine. Lancet, i, 1309–1311.
10. Edvinsson, L., Degueurce, A., Duverger, D., MacKenzie, E. T. and Scatton, B. (1983) Central serotonergic nerves project to the pial vessels of the brain. Nature, 306, 55–57.
11. Foguet, M., Hoyer, D., Pardo, L. A., Parekh, A., Kluxen, F. W., Kalkman, H. O., Stühmer, W. and Lübbert, H. (1992) Cloning and functional characterization of the rat stomach fundus serotonin receptor. EMBO J., 11, 3481–3487.
12. Fozard, J. R. and Gray, J. A. (1989) 5‐HT 1C receptor activation: a key step in the initiation of migraine Trends Pharmacol. Sci., 10, 307–309.
13. Fozard, J. R. and Kalkman, H. O. (1992) 5‐HT in nervous system disease and migraine. Curr. Opin. Neurol. Neurosurg., 5, 496–502.
14. Fozard, J. R. and Kalkman, H. O. (1994) 5‐Hydroxytryptamine (5‐HT) and the initiation of migraine: new perspectives. Naunyn Schmied. Arch. Pharmacol., 350, 225–229.
15. Goadsby, P. J., Edvinsson, L. and Ekman, R. (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol., 23, 193–196.
16. Gomersall, J. D. and Stuart, A. (1973) Amitryptiline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J. Neurol. Neurosurg. Psychiat., 36, 684–690.
17. Humphrey, P. P., Feniuk, W., Marriott, A. S., Tanner, R. J., Jackson, M. R. and Tucker, M. L. (1991) Preclinical studies on the anti‐migraine drug, sumatriptan. Eur. Neurol., 31, 282–290.
18. Jarman, J., Glover, V. and Sandler, M. (1991) Release of (14 C)5‐hydroxytryptamine from human platelets by red wine. Life Sci., 48, 2297–2300.
19. Kalkman, H. O. (1994) Is migraine prophylactic activity caused by 5‐HT 2B or 5‐HT 2C receptor blockade Life Sci., 54, 641–644.
20. Kalkman, H. O., Tekstra, J. and Lübbert, H. (1993) Migraine prophylaxis by 5‐HT 2B receptor blockade Pharmacol. Toxicol., 72 (Suppl. 2), 18.
21. Kluxen, F. W., Bruns, C. and Lübbert, H. (1992) Expression cloning of a rat brain somatostatin receptor cDNA. Proc. Natl Acad. Sci. USA, 89, 4618–4622.
22. Lance, J. W., Anthony, M. and Somerville, B. (1970) Comparative trial of serotonin antagonists in the management of migraine. Br. Med. J., ii, 327–330.
23. Lauritzen, M. (1994) Pathophysiology of the migraine aura. The spreading depression theory. Brain, 117, 199–210.
24. Lauritzen, M. and Olesen, J. (1984) Regional cerebral blood flow during migraine attacks by xenon‐133 inhalation and emission tomography. Brain, 107, 447–461.
25. Leao, A. A. P. (1944) Spreading depression of activity in the cerebral cortex. J. Neurophysiol., 7, 359–390.
26. Leff, P. and Martin, G. R. (1986) Peripheral 5‐HT 2 ‐like receptors. Can they be classified with the available antagonists Br. J. Pharmacol., 88, 585–593.
27. Monro, P., Swade, C. and Coppen, A. (1985) Mianserin in the prophylaxis of migraine: a double‐blind study. Acta Psychiat. Scand., 72, 98–103.
28. Moskowitz, M. A. (1990) Basic mechanisms in vascular headache. Neurol. Clin., 8, 801–815.
29. Moskowitz, M. A. (1993) Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology, 43, 16–20.
30. Moskowitz, M. A. and Macfarlane, R. (1993) Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc. Brain Metab. Rev., 5, 159–177.
31. Moskowitz, M. A., Reinhard, J. F. J., Romero, J., Melamed, E. and Pettibone, D. J. (1979) Neurotransmitters and the fifth cranial nerve: is there a relationship to the headache phase of migraine Lancet, ii, 883–885.
32. Olesen, J. (1992) Cerebral blood flow in migraine with aura. Pathol. Biol. (Paris), 40, 318–324.
33. Olesen, J. and Lipton, R. B. (1994) Migraine classification and diagnosis. International Headache Society criteria. Neurology, 44, S6–10.
34. Olesen, J., Thomsen, L. L. and Iversen, H. (1994) Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol. Sci., 15, 149–153.
35. Ottosson, A. L., Jansen, I., Langemark, M., Olesen, J. and Edvinsson, L. (1991) Histamine receptors in the isolated human middle meningeal artery. A comparison with cerebral and temporal arteries. Cephalalgia, 11, 183–188.
36. Peroutka, S. J. (1993) 5‐Hydroxytryptamine receptor subtypes and the pharmacology of migraine. Neurology, 43, 34–38.
37. Peroutka, S. J. and McCarthy, B. G. (1989) Sumatriptan (GR 43175) interacts selectively with 5‐HT 1B and 5‐HT 1D binding sites. Eur. J. Pharmacol., 163, 133–136.
38. Rebeck, G. W., Maynard, K. I., Hyman, B. T. and Moskowitz, M. A. (1994) Selective 5‐HT 1Dα serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development. Proc. Natl Acad. Sci. USA, 91, 3666–3669.
39. Russell, D. (1979) Cluster headache: trial of a combined histamine H1 and H2 antagonist treatment. J. Neurol. Neurosurg. Psychiat., 42, 668–669.
40. Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
41. Saper, J. R. (1978) Migraine, II. Treatment. J. Am. Med. Assoc., 239, 2480–2484.
42. Schmuck, K., Ullmer, C., Engels, P. and Lübbert, H. (1994) Cloning and functional characterization of the human 5‐HT 2B serotonin receptor. FEBS Lett., 342, 85–90.
43. Seuwen, K., Lagarde, A. and Pouyssegur, J. (1988) Deregulation of hamster fibroblast proliferation by mutated ras oncogenes is not mediated by constitutive activation of phosphoinositide‐specific phospholipase C. EMBO J., 7, 161–168.
44. Sjaastad, O. and Stensrud, P. (1972) Clinical trial of a beta‐receptor blocking agent (LB46) in migraine prophylaxis. Acta Neurol. Scand., 48, 124–128.
45. Sommerville, B. N. (1976) Platelet‐bound and free serotonin levels in jugular and forearm venous blood during migraine. Neurology, 26, 41–45.
46. Toda, N. (1990) Mechanism underlying responses to histamine of isolated monkey and human cerebral arteries. Am. J. Physiol., 258, H311–H317.
47. Ullmer, C., Schmuck, K., Kalkman, H. O. and Lübbert, H. (1995) Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett., 370, 215–221.
48. Wei, E. P., Moskowitz, M. A., Boccalini, P. and Kontos, H. A. (1992) Calcitonin gene‐related peptide mediates nitro‐glycerine and sodium nitroprusside‐induced vasodilation in feline cerebral arterioles. Circ. Res., 70, 1313–1319.
49. Widerö, T. E. and Vigander, T. (1974) Propranolol in the treatment of migraine. Br. Med. J., ii, 699–701.
50. Wolff, H. G. (1963) Headache and Other Head Pain. Oxford University Press, New York.